albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase 1b/2 Study (ESMO 2025) - No abstract available

Metastases • P1/2 data • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Extended Survival with Pancreatic Carcinosarcoma: A Case Report and Literature Review. (PubMed, Curr Oncol) - "We present a case of a 71-year-old male patient diagnosed with metastatic pancreatic carcinosarcoma who received four lines of palliative-intent treatment: gemcitabine and nab-paclitaxel, modified FOLFIRINOX, GTX, and doxorubicin. With careful selection of chemotherapeutic regimen as well as his ability to tolerate four lines of treatment, this resulted in an unprecedented 26-month survival. We also reviewed the literature on the histopathology, diagnosis, and treatment of this rare entity."

Journal • Review • Carcinosarcoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Sarcoma • Solid Tumor

BELLA: A Phase 2 Study of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (ESMO 2025) - No abstract available

Clinical • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: Joseph J. Cullen | Active, not recruiting ➔ Completed | N=65 ➔ 40

Enrollment change • Trial completion • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

NEO-GAP: Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed

Trial completion • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Enrolling by invitation | Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd

New P1 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC (IASLC-WCLC 2025) - "Patients received 2-4 cycles of induction TIS plus nab-paclitaxel and platinum. A notable proportion of patients were enabled to receive radical surgery and attained good pathological response. Recruitment is ongoing, and efficacy and safety will be continuously monitored."

Clinical • Surgery • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

Dr O’Reilly on the Potential of TTFields in Unresectable, Locally Advanced Pancreatic Cancer (OncLive) - "Eileen M. O'Reilly, MD...discussed the potential of tumor treating fields (TTFields) in patients with unresectable, locally advanced pancreatic adenocarcinoma. The randomized, open-label, global, multicenter phase 3 PANOVA-3 trial (NCT03377491) evaluated gemcitabine plus nab-paclitaxel (Abraxane) with or without TTFields for the treatment of patients with newly diagnosed unresectable, locally advanced pancreatic adenocarcinoma. Of note, the primary end point was overall survival (OS), with secondary end points including progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR)."

Video

Long Progression-Free Survival With Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series (IASLC-WCLC 2025) - "After relapsing in Jun 2010, he received various chemotherapy regimens until Aug 2012, followed by icotinib, then osimertinib (found T790M mutation) was administered as fifth-line therapy (Dec 2017-May 2023) combined with anlotinib from 2020, and nab-paclitaxel plus sugemalimab as sixth-line (May-Oct 2023). For seventh-line treatment, sunvozertinib 150 mg QD with vinorelbine maintained for over 12 months...After relapsing in 2016, she received gefitinib...Table 1. Case summary (Data cutoff: Dec 11, 2024)"

Clinical • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

KEYMAKER-U01 Substudy 01G: Pembrolizumab+Patritumab Deruxtecan±Chemotherapy in Previously Untreated Stage IV NSCLC (IASLC-WCLC 2025) - P, P2 | "Participants in Arm 1 will receive pembrolizumab 200 mg IV Q3W up to 35 cycles with carboplatin area under the curve 5 mg/ml/min (nonsquamous histology) or 6 (squamous) IV Q3W for 4 cycles, and either paclitaxel 200 mg/m 2 IV Q3W or nab-paclitaxel 100 mg/m 2 IV QW for squamous histology, or pemetrexed 500 mg/m 2 IV Q3W for nonsquamous histology. The secondary objectives are duration of response and PFS per RECIST v1.1 by BICR, and OS. Enrollment for this study will be ongoing globally."

IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • ERBB3 • HER-2 • PD-L1 • ROS1

Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel. (PubMed, J Chemother) - "Therefore, in the future, it is of great importance that a comprehensive and systematic assessment regarding the individual risks for patients be carried out in a meticulous manner. Relevant research should be conducted into the mechanisms underlying peripheral neuropathy, with particular attention to the role of individual factors."

Journal • Hematological Disorders • Obesity • Oncology • Pain

Gut microbial diversity is preserved through localised chemo-immunotherapy delivery in a KPC mouse model of pancreatic cancer. (PubMed, J Control Release) - "Using a syngeneic KPC mouse model of PDAC, we compared systemic versus implant-based delivery of gemcitabine/nab-paclitaxel and anti-CD40/anti-PD1 antibodies. This is the first study to demonstrate that spatial control of drug exposure via localised delivery can protect the gut microbiome and modulate systemic immunity in PDAC. These findings subsequently provide proof-of-concept that implant-based approaches can enhance tolerability and efficacy of chemo-immunotherapy by minimising microbiome disruption."

Journal • Preclinical • Inflammatory Bowel Disease • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Sublobar Resection Versus Lobectomy in Peripheral NSCLC After Neoadjuvant Chemoimmunotherapy: A Retrospective Study (IASLC-WCLC 2025) - "Methods : Patients with stage IB-IIIA (IASLC 9th edition) peripheral NSCLC who received neoadjuvant chemoimmunotherapy (paclitaxel/nab-paclitaxel/pemetrexed plus carboplatin/cisplatin and nivolumab) at Guangdong Provincial People's Hospital (2018-2024) and underwent surgery after MDT evaluation were retrospectively analyzed. Conclusions : For peripheral NSCLC patients achieving PR/CR after neoadjuvant chemoimmunotherapy, sublobar resection with lymphadenectomy demonstrated comparable DFS to lobectomy, while preserving more lung function, accelerating postoperative recovery. However, this study is limited by its small sample size and short follow-up duration, necessitating validation through prospective trials with extended follow-up."

IO biomarker • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • PD-L1

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. (PubMed, Eur J Cancer) - P2 | "NCRCN regimen was a promising treatment strategy with a high surgical conversion rate in initially inoperable patients with LAESCC. TRIAL REGISTRATION CLINICALTRIALS."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Neutropenia • Oncology • Squamous Cell Carcinoma • CD8 • FOXP3

Efficacy and Safety of Ivonescimab Plus Chemotherapy for Recurrent/Metastatic Thymic Carcinoma: A Phase II Study (iThyme) (IASLC-WCLC 2025) - P2 | "Patients receive ivonescimab (20 mg/kg, intravenously every 3 weeks) in combination with paclitaxel (175 mg/m2) or albumin-bound paclitaxel (260 mg/m2) and carboplatin (AUC 5) for 4-6 cycles, followed by maintenance therapy with ivonescimab until disease progression or unacceptable toxicity. Using Simon' s optimal design (α=0.05, β=0.20), 8 patients are enrolled in Stage I; if ≤3 progressions occur by 6 months, Stage II proceeds to total 24 patients. Success is defined as ≤10 progressions at 6 months in the full cohort."

Clinical • IO biomarker • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. (PubMed, J Health Econ Outcomes Res) - "FFX and mFFX costs were largely driven by chemotherapy administration and G-CSF costs, while GnP costs were driven by chemotherapy drug costs. To fully assess the economic impact of mPDAC in 1L treatment, it is essential to consider both the total cost and the individual cost components, such as chemotherapy drugs, administration, and supportive care costs."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

SKB264-Ⅲ-13: A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy (clinicaltrials.gov) - P3 | N=430 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma. (PubMed, Biomaterials) - "To address these challenges, we developed GE11 peptide-modified polyphenol-iron chelate nanoparticles for co-delivery the long carbon chain-modified gemcitabine and the DHODH inhibitor leflunomide, with peptide modification enabling nanoparticles to target PDAC cells with high expression of epidermal growth factor receptor. In an in situ pancreatic cancer mouse model, this strategy exhibited superior anti-tumor efficacy compared to the standard AG chemotherapy regimen (nab-paclitaxel and gemcitabine), even at a 6.3-fold lower gemcitabine concentration. These findings underscore the potential of this approach as a highly effective therapeutic strategy for PDAC treatment."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR

Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC (IASLC-WCLC 2025) - P2 | "Patients received neoadjuvant therapy comprising Sintilimab, nab-paclitaxel, and carboplatin for 2-3 cycles, followed by surgical resection and systematic nodal dissection. Conclusions : Neoadjuvant chemoimmunotherapy has significantly improved long-term survival for patients with potentially resectable stage IIIA/IIIB NSCLC. TLS abundance enables precise prognosis stratification and personalized treatment strategies, thereby optimizing outcomes."

Biomarker • Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • BCL6 • CD20 • CD21 • PD-L1

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P3 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP)in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) (ESMO 2025) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma (IASLC-WCLC 2025) - "Given the unmet clinical need for this rare malignancy, we conducted this study to evaluate the efficacy and safety of adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy for unresectable locally advanced thymic carcinoma. Conclusions : In patients with unresectable locally advanced thymic carcinoma, neoadjuvant adebrelimab combined with chemotherapy demonstrated promising efficacy and an acceptable safety profile. The trial is still ongoing to complete accrual in stage II."

Clinical • Metastases • Leukopenia • Neutropenia • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

A Prospective Interventional Study of Preoperative PD-1 Monoclonal Antibody (Toripalimab) Combined with Gemcitabine and Albumin-bound Paclitaxel for Borderline Resectable and Locally Advanced Pancreatic Cancer (ESMO 2025) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor

High response rate of gemcitabine, nab-paclitaxel, and S-1 in patients with locally advanced or metastatic pancreatic cancer: results from a phase II GeNeS1S Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancer (ESMO 2025) - No abstract available

Clinical • Oncology • Pancreatic Cancer • Solid Tumor